Close Menu

NEW YORK (360Dx) – T2 Biosystems reported after the market closed on Thursday that its fourth quarter revenues rose 6 percent year over year, but the results fell short of analysts' expectations, triggering a sell-off of the firm's stock.

In Friday morning trading on the Nasdaq, T2 Bio's shares were down more than 19 percent at $2.52.

For the three months ended Dec. 31, 2018, the company posted revenues of $1.8 million, compared to $1.7 million in Q4 2017, and lower than analysts' average estimate of $2.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.